CD28 and neoplasm: The engineered, bi-specific, therapeutic, chimeric aptamers (MRP1-CD28) could activate the tumor-infiltrating lymphocyte (TILs) against melanoma tumors and showed strong antitumor activity through inducing an immune response in vivo [114,123,124].